ALLYRNA, an innovative small molecule drug developer focusing on first-in-class cancer treatments, has secured nearly $10 million in seed funding. The round was co-led by Qiji Investment, Gaorong, and Jifeng, with strategic follow-on investment from U.S.-based Plaisance Capital.

CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- Alltrna , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Dr. Nerissa Kreher as Chief Medical Officer (CMO). Dr. Kreher brings decades of expertise in rare disease drug development, including extensive experience in clinical development, medical affairs, and regulatory strategy across both early- and late-stage programs."We are thrilled to welcome Nerissa to the Alltrna leadership team as we advance our first tRNA development candidates to the clinic for liver Stop Codon Disease," said Michelle C. Werner, CEO of Alltrna

CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- Alltrna , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11 in Baltimore and a talk and two poster presentations at TIDES USA 2024 taking place May 14-17 digitally and in-person in Boston.Details of the presentations are as follows:ASGCT 27th Annual MeetingPoster Title: tRNA Therapeutics to Treat Stop Codon DiseaseSession Date & Time: May 9, 12:00 PM to 7:00 PM ETPresenter: Stephen Eichhorn, Ph.D., Head of Computational and Molecular Biology, AlltrnaPresentation Room: Exhibit HallSession Title: Oligonucleotide TherapeuticsAbstract Number: 1221TIDES USA 2024Talk Title: Manufacturing Strategies for Chemically Modified tRNAsSession Date & Time: May 17, 5:00 PM to 5:30 PM ETPresenter: William Kiesman, Ph.D., Chief Technology Officer, AlltrnaSession Title: Oligonucleotide Chemistry, Manufacturing, and ControlsPoster Title: Building 3-D homology models to support tRNA structure-based drug designPresenter: Audrey Hughes, Ph.D., Scientist II, Computational Chemistry, AlltrnaPoster Title: Quantification of Tissue Delivery for tRNA Therapeutics in LNP FormulationsPresenter: W. George Lai, Ph.D., Head of DMPK, Drug Safety and Clinical Pharmacology, AlltrnaPosters will be displayed onsite in the exhibit hall throughout TIDES USA 2024.About Stop Codon DiseaseStop Codon Disease encompasses thousands of rare and common diseases that stem from premature termination codons (PTC) also called nonsense mutations, where the code for an amino acid has been mutated into a premature "stop" codon. This results in a truncated or shortened protein product with no or altered biological activity that causes disease. Approximately 10% of all people with a genetic disease have Stop Codon Disease, representing approximately 30 million people worldwide. Alltrna is engineering tRNA medicines that can read these PTC mutations and deliver the desired amino acid, thereby restoring the production of the full-length protein.About AlltrnaAlltrna unlocks tRNA biology to treat disease. The company's platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential